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Background: When experiencing sleep problems for the first time, consumers may often 
approach community pharmacists for advice as they are easily accessible health care profes-
sionals in the community. In Australian community pharmacies there are no specific tools 
available for use by pharmacists to assist with the assessment and handling of consumers with 
sleep enquiries.
Objective: To assess the feasibility of improving the detection of sleep disorders within the 
community through the pilot of a newly developed Community Pharmacy Sleep Assessment 
Tool (COP-SAT).
Method: The COP-SAT was designed to incorporate elements from a number of existing, 
standardized, and validated clinical screening measures. The COP-SAT was trialed in four 
Australian community pharmacies over a 4-week period.
Key findings: A total of 241 community pharmacy consumers were assessed using the  COP-SAT. 
A total of 74 (30.7%) were assessed as being at risk of insomnia, 26 (10.7%) were at risk of 
 daytime sleepiness, 19 (7.9%) were at risk of obstructive sleep apnea, and 121 (50.2%) were 
regular  snorers. A total of 116 (48.1%) participants indicated that they consume caffeine before 
bedtime, of which 55 (47%) had associated symptoms of sleep onset insomnia.  Moreover, 
85 (35%) consumed alcohol before bedtime, of which 50 (58%) experienced fragmented sleep, 
50 (58%) were regular snorers, and nine (10.6%) had apnea symptoms. The COP-SAT was feasible 
in the community pharmacy setting. The prevalence of sleep disorders in the sampled population 
was high, but generally consistent with previous studies on the general population.
Conclusion: A large proportion of participants reported sleep disorder symptoms, and a link 
was found between the consumption of alcohol and caffeine substances at bedtime and associ-
ated symptoms. While larger studies are needed to assess the clinical properties of the tool, the 
results of this feasibility study have demonstrated that the COP-SAT may be a practical tool for 
the identification of patients at risk of developing sleep disorders in the community.
Keywords: sleep disorder, insomnia, sleep apnea, sleep assessment, pharmacy
Background
A sleep disorder is a medical illness or poor sleep behavior that leads to inadequate 
amounts of sleep or poor quality sleep.1 The most common sleep disorders include 
insomnia, snoring, and obstructive sleep apnea (OSA).2 In 2010, sleep disorders 
affected 1.5 million Australians and directly contributed to an estimated 818 million 
Australian dollars of health expenditure.1
Sleep disorders are highly prevalent in the community and are associated 
with significant personal and socioeconomic burden, yet they remain largely 
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 under-diagnosed and inadequately treated.3,4 The importance 
of the prevention of sleep disorders, as well as improved 
sleep management and assessment is becoming increas-
ingly recognized. International estimates suggest that only 
one in 2000 patients with chronic insomnia consult their 
physicians for help, while the remainder either do nothing or 
resort to self-treatment with over the counter (OTC) medica-
tions, including complementary and alternative medications 
(CAMs) such as natural supplements, alternative therapies, 
and/or alcohol.5,6
In Australia, legislation regarding pharmaceutical 
 medicines for each Australian state and territory are guided 
by the Federal Government’s Standard for the Uniform 
 Scheduling of Medicines and Poisons (SUSMP).7 The 
Standard for the Uniform Scheduling of Medicines and 
Poisons classifies medicines and poisons into nine schedules, 
of which schedules two, three, four, and eight consist of 
medicines for human therapeutic use.7
The term OTC refers to medicines that can be obtained 
without a doctor’s prescription or non-prescription medi-
cines, and includes both schedule two (pharmacy medicines) 
and schedule three (pharmacist only) medicines which are 
described below:8
•	 Schedule two pharmacy medicines: “Substances, the safe 
use of which may require advice from a pharmacist and 
which should be available from a pharmacy.”7
•	 Schedule three pharmacist only medicines: “Substances, 
the safe use of which require professional advice but 
which should be available to the public from a pharmacist 
without a prescription.”7
Specifically, when in need of sleep medicines or products 
to aid in alleviating sleep problems, consumers are able to 
purchase a variety of OTC sleep aid devices (eg, acupressure 
antisnore rings, antisnore nasal strips), herbal and hormonal 
CAMs (eg, valerian and melatonin), and sedating antihista-
mines (eg, doxylamine and diphenhydramine). While the sale 
of sleep aid devices and complementary preparations do not 
require the intervention of a pharmacist in Australia, sedating 
antihistamines are classified as schedule three medicines, 
and their provision requires assessment and counseling by 
a pharmacist.7
Community pharmacies are often the most easily accessi-
ble health care locations in the community; therefore, they are 
often the first point of care for individuals with self-perceived 
sleep problems.4 Studies have shown that pharmacists may 
be successfully trained to identify patients who are at risk for 
developing sleep disorders;4,9 however, there are currently 
no specific tools available for use by Australian community 
pharmacists to determine those at risk. An assessment device 
or tool must be time-efficient, cost-effective, and practical, 
in order to be readily incorporated into the busy community 
pharmacy environment.10 Questionnaires that investigate 
the symptoms, lifestyle factors, and underlying conditions 
associated with sleep disorder risk are ideal tools for this 
purpose.10,11
There are a variety of sleep disorder questionnaires avail-
able for diagnostic purposes.12,13 Most of these were developed 
by specialist sleep clinics and for use in clinic populations.12 
Limited studies have trialed sleep disorder screening across 
international community pharmacies.4,9,14,15 Several success-
ful feasibility trials examining sleep disorder screening have 
been undertaken in Australia by Fuller et al;9,14,15 however, 
no single, pharmacy-administered, standardized question-
naire or scale for the assessment of sleep disorder risk in 
the community has been nationally implemented,12,13,16 thus 
presenting a clinical and research gap.
The aim of this study was to assess the feasibility of 
improving the detection of sleep disorders within the com-
munity through the pilot of a newly developed Community 
Pharmacy Sleep Assessment Tool (COP-SAT). A further aim 
was to determine the potential contributors to the develop-
ment of sleep problems with a focus on exploring the use of 
medications related to sleep, and any apparent links between 
alcohol and caffeine use and the occurrence of sleep disorder 
symptoms.
Methods
Tool development
An extensive literature review was conducted investigating 
the available research in the area of sleep, sleep disorder 
prevalence, sleep screening tools, and community pharmacy 
management of sleep disorders. The COP-SAT was devel-
oped based on information found in the literature, which 
outlined that the most prevalent sleep disorders in Australia 
are insomnia, daytime sleepiness, snoring, and sleep apnea. 
COP-SAT questions were worded and designed accordingly, 
with assistance from experts in the field of sleep disorders 
(SS and JD). The COP-SAT consisted of 14 questions and 
assessed the level of risk for four major sleep disorder 
 symptoms: insomnia, daytime sleepiness, snoring, and 
apneas. Two existing and validated measures with good 
psychometric properties, the Epworth Sleepiness Scale 
(ESS)17 and Insomnia Severity Index (ISI)11 were modified 
and included as part of the tool. Questions that assessed snor-
ing and apnea symptoms were recommended by experts SS 
and JD based on their practical experience with assessment 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4
Kashyap et al
Integrated Pharmacy Research and Practice 2012:1
tools, as well as with the investigation of patients in the sleep 
disorder clinic environment.
Questions assessing current and past prescription medica-
tion intake as well as questions on alcohol, caffeine, nicotine, 
marijuana, and OTC or CAM use were added to the COP-SAT 
to maximize its breadth as a screening tool. The researcher 
facilitated the process of completing the COP-SAT ques-
tions with consumers, and therefore terms such as “natural 
supplements” were explained and translated to the consumer 
at the time of implementation. The full COP-SAT is shown 
in Figure S1.
Setting
Four community pharmacies in suburban Brisbane,  Australia 
were selected purposively and by convenience in an attempt to 
achieve variation in pharmacy and consumer  demographics. 
The demographic details of the pharmacies are shown in 
Table 1. The Socioeconomic Index for Area codes are shown 
in Table 1 as an indication of socioeconomic status for the 
area in which each pharmacy was located; the higher an area’s 
index value, the less disadvantaged that area is compared 
with other areas.18
Feasibility of the COP-SAT process
The feasibility of the COP-SAT surveying process was 
tested on the initial four consumers in the first pharmacy. 
It was intended that the results from these four consumers 
would be considered a test pilot of the COP-SAT process; 
however, since no issues were identified and refinement of 
the COP-SAT form was not needed, the results of these four 
consumers were included into the data analysis.
Participant recruitment
Community pharmacy consumers who were either waiting 
for prescriptions to be dispensed, or who were shopping in the 
pharmacy aisles were approached by a researcher and invited 
to participate in the sleep survey. The researcher approached 
potential participants by asking, “Would you be interested in 
a quick 2 to 5-minute survey while you’re waiting?” Any 
consumer in the pharmacy was asked to  participate, not only 
those who presented for OTC sleep requests or  prescriptions. 
Data were collected between 9 am and 5 pm for 1 week 
 (Monday to Friday), with no restrictions on gender or num-
ber of customers approached. Recruited participants were 
required to be 18 years or older. Verbal consent was obtained 
from all participants. Participants suffering from existing 
sleep conditions or any other medical conditions had these 
details recorded on the COP-SAT form.
Data collection
The researcher (KK) verbally asked each question and 
recorded participants’ answers directly onto the COP-SAT 
form. Data from the COP-SAT forms were later scored 
and entered into an electronic Microsoft Access® database 
(Microsoft Corporation, Redmond, WA). All data were dei-
dentified prior to data entry.
Data analysis
The risk of insomnia and daytime sleepiness scores were 
calculated using the recommended cut-off scores for the ISI 
and ESS instruments, respectively. An ESS score between 
0 and 10 was considered normal; a score between 11 and 
15 was considered to represent moderate daytime sleepi-
ness risk; and a score between 16 and 24 was considered to 
represent an excessive daytime sleepiness risk. An ISI score 
between 0 and 7 was considered normal; a score between 8 
and 14 suggested a subthreshold risk of insomnia; a score 
between 15 and 21 indicated a risk of clinically significant 
insomnia of moderate severity; and a score between 22 and 
28 was considered to represent a risk of developing clini-
cally severe insomnia.11 A positive risk of sleep apnea was 
indicated if the participant answered “yes” to all sections 
in question one of the COP-SAT. Question one assessed 
whether the participant woke up during the night with chok-
ing or suffocating symptoms, and also assessed the monthly 
frequency of this symptom as well as whether a partner had 
Table 1 Sample pharmacy characteristics
Pharmacy Number of  
consumers
Median age  
[range]
Gender 
M:F
SEIFA  
score
Location Chain Independent Type
1 95 44 [18–90] 37:58 1062 City  Shopping center
2 41 36 [18–85] 12:29 1047 City  Shopping center
3 48 48 [18–84] 24:24 1010 Suburban  Big box 
discounter
4 57 50 [20–83] 29:28 986 Suburban  Strip mall
Notes: Reference score for the whole of Australia = 1000; relatively lower scores indicate lower socioeconomic status.
Abbreviations: M, male; F, female; SEiFA, Socioeconomic index for Areas.
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noticed the participants exhibiting breathing problems while 
they slept.
Furthermore, participants were considered snorers if they 
answered “yes” to question two of the COP-SAT, which asked 
them whether they knew or had been told by a partner that 
they snored during sleep, and how frequent the snoring was 
(some nights, most nights, or every night).
Statistical analysis
All statistical analyses were performed using the Number 
Cruncher Statistical Software™ (NCSS, LLC, Kaysville, 
Utah). Univariate logistic regression was used to estimate the 
odds ratios (OR) of sleep disorder symptoms and their asso-
ciation with evening caffeine and alcohol consumption.
Ethics approval
Ethical approval was provided by the University of Queen-
sland, School Of Pharmacy Human Research Ethics Commit-
tee (Approval number 2010/29). The owner of each pharmacy 
provided verbal consent for their pharmacy’s participation 
in the data collection.
Results
A total of 241 consumers were recruited during the 1-month 
data collection period. The number of consumers who refused 
to participate was not recorded; however, the research-
ers noted that the common reason for refusal was that the 
consumers were “too busy” and “don’t have time.” The 
median age range for participants was 45 (14–90) years. In 
all, 102 (42.3%) participants were male and 139 (57.7%) 
were female.
A total of 74 (30.7%) consumers reported symptoms sug-
gestive of insomnia by conventional ISI criteria; 56 (23.2%) 
were classed as being at risk for subthreshold insomnia; 
14 (5.9%) were at risk of moderate clinical insomnia; and 
four (1.1%) were at risk of severe clinical insomnia. A total 
of 26 (10.7%) consumers reported experiencing symptoms 
of daytime sleepiness as per the ESS criteria, 20 (8.3%) were 
classed as being at risk of moderate daytime sleepiness, and 
six (2.5%) were classed as being at risk of severe daytime 
sleepiness (Table 2). A total of 121 consumers reported that 
they were regular snorers (greater than one episode of snoring 
per week), and 19 reported experiencing both snoring and 
choking symptoms suggestive of sleep apnea.
Participants were asked to list all the medications they 
were consuming, including any products or substances they 
felt they were specifically taking to aid with sleep. Many 
participants were unaware that some of their medications or 
substances affected their sleep, yet some participants listed 
substances that they “felt” had an effect on their sleep which 
actually did not (eg, paracetamol) (Table 3). A total of 55 
(22.8%) participants indicated that they regularly consumed 
sedating substances to aid with sleep, with seven (2.9%) 
participants consuming more than one sedative agent. Seven 
(2.9%) participants reported marijuana use.
Eighty-five (35%) participants indicated that they con-
sumed alcoholic beverages less than 5 hours prior to bedtime; 
however, only six (2.5%) participants said they were consum-
ing these alcoholic beverages specifically to aid with sleep. 
Of the 85 (35%) participants who consumed alcohol less than 
5 hours before bedtime, 50 (58%) also reported experiencing 
fragmented sleep (sleep maintenance insomnia) (OR = 1.9 
(1.1–3.3)), 50 (58%) were regular snorers (OR = 1.84 (1.06–
3.17)), and nine (10.6%) had experienced apnea symptoms 
(OR = 0.61 (0.27–1.4)). Of the 116 (48.1%) community 
consumers that consumed caffeine less than 5 hours prior 
Table 2 Prevalence of sleep disorder risks (n = 241)
Sleep disorder risk n (%)
Sub-threshold insomnia 56 (23.2%)
Moderate insomnia 14 (5.9%)
Severe insomnia 4 (1.1%)
Total at risk of insomnia 74 (30.7%)
Moderate daytime sleepiness 20 (8.3%)
Severe daytime sleepiness 6 (2.5%)
Total at risk of daytime sleepiness 26 (10.7%)
Total snorers 121 (50.2%)
Total at risk of sleep apnea 19 (7.9%)
Table 3 Medications or substances that may affect sleep as 
reported by participants (n = 241)
Medication/substance n (%)
Prescription medications 34 (14%)
 Benzodiazepines 22 (9%)
 non-benzodiazepine hypnotics 5 (2%)
 Antidepressants 2 (1%)
 Opioids 2 (1%)
Over the counter medications 17 (7.1%)
 Sedating antihistamines 9 (3.7%)
 Herbal 3 (1.2%)
 Paracetamol 5 (2%)
Other/unidentified/overseas products 4 (1.7%)
Alcohol specifically for aid of sleep 6 (2.5%)
 Wine 96 (39.9%)
 Beer 72 (29.9%)
 Spirits 58 (24.1%)
 Coffee 164 (68%)
 Tea 173 (71.8%)
nicotine (cigarette smoking) 37 (15.4%)
Marijuana 7 (2.9%)
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to bedtime, 55 (47%) of them also reported experiencing 
associated symptoms of sleep onset insomnia (OR = 6.6 
(3.5–12.7)) (Figure 1). Of the 55 (22.8%) participants who 
admitted to regular consumption of sedating substances, 
28 reported symptoms suggestive of insomnia.
Discussion
This study found that the COP-SAT was a feasible sleep 
assessment tool with potential for use in community phar-
macies in order to detect sleep disorder symptoms, assess 
sleep habits, and to determine sleep aid use among com-
munity pharmacy consumers. Further investigation will be 
required to validate the COP-SAT in community practice. It is 
important to note that in this study a researcher implemented 
the COP-SAT, and practicing community pharmacists or 
pharmacy staff members were not involved; therefore, future 
studies will require trial of the COP-SAT by pharmacists and 
pharmacy assistants in order to determine the acceptability 
and usability of this tool in practice. This may ultimately 
change or reduce the acceptability or uptake of this tool by 
pharmacists and pharmacy staff. Although pharmacists were 
not surveyed to determine their general acceptability of the 
COP-SAT, by allowing this research to be conducted they 
addressed an understanding of the importance of improved 
sleep management in community pharmacy.
The questions included within the COP-SAT were taken 
from existing validated measures for sleep (ISI and ESS), and 
these measures are self-administrable psychometric tools;11,17 
therefore, the initial implementation of the COP-SAT would 
not necessarily require a pharmacist or pharmacy assistant. 
The COP-SAT would lend itself very readily to the idea 
of online or “kiosk” administration given that it may be 
self-administered by consumers. This may reduce time and 
cost burdens to the pharmacy. However, it should be noted 
that a pharmacist or trained pharmacy assistant would still 
be required to interpret the COP-SAT results and provide 
targeted counseling and advice to “at-risk” consumers.
Furthermore, it is important to highlight that the partici-
pants included in this study were all consumers of community 
pharmacies – whether attending for their cardiovascular 
medications, for sleep medications, or merely for purchases 
of cosmetics in the pharmacy – and not specifically consum-
ers with sleep-related concerns or problems. Therefore it is of 
interest that the presence of sleep issues and problems in this 
sample were prevalent. Almost half of the participants gener-
ated responses indicative of sleep and wakefulness disorders 
(30.7% insomnia, 10.7% daytime sleepiness, 7.9% OSA). 
International estimates range from 9% to 36% for insom-
nia,19 8.7% to 20% for daytime sleepiness,20 and 2% to 10% 
for OSA.21 It was interesting to note that the prevalence for 
insomnia and OSA among the participants in this study was 
at the higher end of the international ranges, while daytime 
sleepiness was comparatively lower. Some authors suggest 
that this variance may be due to the fact that estimates of 
insomnia prevalence vary according to the diagnostic defi-
nition and criteria used.4,22–25 For example, epidemiological 
studies assessing the prevalence of insomnia symptoms with-
out using restrictive criteria have reported prevalence rates 
of approximately 30% in the general population.24  However, 
studies that assessed the prevalence of insomnia symptoms 
when daytime consequences are taken into account reported 
prevalence rates of between 9% and 15%.24
The use of the COP-SAT may be of greater benefit in 
targeted consumer populations such as those attending 
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Figure 1 Alcohol and caffeine consumption at bedtime and associated sleep symptoms.
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 community pharmacies with specific sleep requests or 
problems, and this should be considered for future studies. 
Currently, there are no standardized tools or surveys available 
for use among Australian community pharmacists in assess-
ing consumers with sleep requests or those who attend with 
sleep problems. The targeted use of a sleep-specific tool such 
as the COP-SAT among community pharmacy consumers 
with sleep requests will allow for the enhanced detection of 
specific sleep disorder symptoms, problems, and behaviors 
that are contributing to sleep problems; this will ultimately 
lead to earlier management and increased referral of “at-risk” 
patients to their general practitioners.
Approximately 17% of the study participants were regu-
larly consuming OTC sleep aids. It is not known whether 
these participants had been recommended an OTC sleep 
aid by their health care professional, or whether they were 
self-medicating with these products because the questions 
within the COP-SAT did not allow for this information to 
be distinguished. However, international reports indicate 
that approximately 28% of consumers with sleep problems 
self-medicate with OTC products.4,26 In 2002, Phelan et al27 
investigated the use of OTC sleep aids purchased from 
community pharmacies in England using a self-completed 
questionnaire and found that many purchasers of OTC sleep 
aids still reported long-standing sleep problems over peri-
ods of months to years. Future modifications made to the 
COP-SAT tool will allow for the inclusion of questioning 
on self-medication.
Of the seven (2.9%) participants who admitted to 
marijuana use, only two (0.8%) were aware of the effects 
of marijuana on sleep patterns. Marijuana users were forth-
coming about their illicit drug use when informed about 
the anonymity of their participation. The “kiosk”-style 
implementation of the COP-SAT in the future may allow 
users of illicit drugs to more openly report their drug use, 
which has implications for understanding sleep patterns 
and management options among these individuals.
One of the most significant findings of this study was 
the prevalence of caffeine and alcohol consumption prior 
to bedtime. As shown in Figure 1, many participants who 
reported caffeine or alcohol consumption within 5 hours of 
bedtime were also experiencing associated sleep symptoms. 
More specifically, a positive correlation was noted between 
the types of sleep symptoms: those consuming caffeine at 
bedtime reported experiencing symptoms of sleep onset 
insomnia, and those consuming alcohol at bedtime reported 
experiencing symptoms of both sleep maintenance insomnia 
and snoring. These results showed that while caffeine and 
alcohol intake can interfere with sleep onset and sleep quality 
(thus potentially contributing to sleep problems), participants 
may not be aware of these impacts.
Studies show that impairments in psychomotor perfor-
mance are detectable in as little as 6 hours after consuming 
caffeine, and habitual caffeine use results in a well-established 
withdrawal effect of daytime sleepiness.28 Self-medicating 
insomnia and daytime sleepiness symptoms with substances 
such as caffeine and alcohol is considered a “quick relief ” of 
symptoms for patients; however, these drugs paradoxically 
worsen symptoms.29 The COP-SAT allowed for the increased 
detection of caffeine and alcohol consumption, and for the 
evaluation of its link with sleep problems. Larger studies of 
the COP-SAT in the wider community pharmacy setting will 
be required to verify this effect.
The prevalence of sleep disorder symptoms found through 
the use of the COP-SAT indicated that many individuals in 
society may suffer from potential sleep problems, and that 
these individuals also visit community pharmacies. It is 
possible that these consumers may be escaping detection 
and treatment for their symptoms. Studies have shown that 
pharmacists may be successfully trained to identify patients 
who are at risk for developing sleep disorders, and the com-
munity pharmacy is an ideal location for assisting “at-risk” 
patients.4,14
Studies conducted by Tran et al9 in 2009, and in 2011 by 
Fuller et al14 have investigated the use of sleep assessment 
tools in Australian community pharmacies. These previous 
studies suggested that the use of a sleep tool in a pharmacy 
setting is viable and feasible.9 Tran et al reported similar 
prevalence estimates for insomnia to those of our study 
(33.3% compared to 30.7%); however, they uncovered a 
much higher prevalence of OSA (21.4% compared to 7.9%). 
This could be due to the different measures used for assess-
ing OSA risk. Tran et al also found that many participants 
were not aware that certain medications could affect their 
sleep health.9 Fuller et al also suggested that extended stud-
ies in the area of sleep assessment involving community 
pharmacies as sites for screening should be undertaken.14,15 
Therefore, implementation of the COPSAT tool by trained 
community pharmacists and pharmacy staff, as well as an 
assessment of the usability and acceptability of the COPSAT 
by community pharmacists and their staff would be a future 
implication of this study.
Methodological limitations of this study included that 
the number of consumers who refused to participate was 
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not recorded, meaning that a response rate to the COP-SAT 
could not be determined, which limits the generalizability 
of these findings. The results were not representative of 
the Australian population, or the primary care population; 
however, the findings applied only to pharmacy clients.30 
Furthermore, the pharmacies that were selected to participate 
were purposively chosen for convenience and demographic 
purposes. In addition, the questions used for the assessment 
of sleep apnea and snoring were not the full versions of vali-
dated tools; rather, they were items extracted from validated 
tools. Data were collected between 9 am and 5 pm for 1 week 
(Monday to Friday), and these data collection times were not 
varied as it was not feasible for the researcher. Therefore, the 
opinions of late-night and weekend shoppers have not been 
collected, and this may be considered a limitation. Finally, 
there was no exploration of consumer satisfaction with the 
survey, and a follow-up phase was not conducted to assess 
whether the identification of consumers with sleep problems 
led to changed behaviors or diagnoses.
Conclusion
This study demonstrates the feasibility of using a brief tool 
to identify those at risk of sleep disorders, and to explore 
the link between the use of substances such as caffeine and 
alcohol and sleep disorder risk. Pharmacists, as the most 
accessible health care professionals, can potentially play a key 
role in the improved management of sleep behaviors. Wider 
training and implementation of the COP-SAT in community 
pharmacies as part of a national or community management 
strategy could prove to be beneficial for the identification 
and individualized management of consumers who are “at 
risk” of certain sleep disorders, especially as we realize the 
impact of sleep disorders on public health.
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Supplementary material
COMMUNITY PHARMACY SLEEP SURVEY 
Date ……….                                        Age  .………                             Gender  ………. 
1. Do you ever wake during the night feeling like you are choking or suffocating?
• If yes, how many times has this happened in the last month?   
                                      
• Has anyone ever noticed that you stop breathing when asleep?   
2. Do you snore during sleep?        
• If yes, how often do you snore?  
3. Epworth Sleepiness Scale was included here
4. Insomnia Severity Index was included here
5. Do you currently take anything to help you sleep at night? 
**Include non prescription, over the counter medications, natural supplements, alcohol and caffeine products.  
Please list: …………………………………………………………………………………… 
6. Have you in the past taken anything to help you sleep at night?
**Include non prescription, over the counter medications, natural supplements, alcohol and caffeine products.  
Please list: ……………………………………………………………………………….. 
7. Do you currently take anything to help you stay awake during the day?   
**Include non prescription, over the counter medications, natural supplements, alcohol and caffeine products
Please list: ……………………………………………………………………………… 
8. Haveyou in the past taken anything to help you stay awake during the day?
**Include non prescription, over the counter medications, natural supplements, alcohol and caffeine products.  
Please list: …………………………………………………………………………… 
9. Are you a:       
10. Do you smoke:
11.  Do you drink:
d. beer?
12. Do you regularly consume other food products which contain caffeine? (eg Guarana, Red Bull, cola drinks)
13. What time do you drink the last tea/caffeine drink before going to bed?       ..…… 
14. What time do you drink the last alcoholic drink before going to bed?     ……. 
Figure S1 The COP-SAT.
Abbreviation: COP-SAT, Community Pharmacy Sleep Assessment Tool.
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